openFDA
Cure8 regulatory brief
Yuflyma FDA label update (2026-07-08)
Medications
Anti-TNF
Regulatory Update
Adult patients
Pediatric Patients
Clinicians
Patients On Biologics
Crohn's disease
Why This Matters
This is an FDA label entry for YUFLYMA (an adalimumab product) that confirms Crohn’s disease and ulcerative colitis are listed indications and reiterates serious-infection and malignancy warnings for TNF blockers. Patients and clinicians should be aware of the monitoring and age-specific indications in the label.
Who Should Pay Attention
Patients with Crohn's disease or ulcerative colitis (including pediatric patients 6+ for Crohn's), clinicians prescribing biologics, and caregivers of pediatric patients on TNF blockers.
Study Snapshot
Story typeRegulatory
Evidence typeRegulatory update
Study statusHuman prescription drug
Source depthRegulatory record
What To Know
This DailyMed entry is an FDA drug-label update for YUFLYMA (an adalimumab product). The label lists indications including treatment of moderately to severely active Crohn’s disease in adults and children 6 years and older, and ulcerative colitis in adults, and includes boxed warnings about serious infections and malignancy seen with TNF blockers.
The prescribing information emphasizes testing for latent tuberculosis before and during treatment, monitoring for serious infections and malignancy, and notes post-marketing reports of rare hepatosplenic T‑cell lymphoma in adolescent and young adult IBD patients treated with TNF blockers.
The label also describes concomitant immunosuppressant use (for example methotrexate or corticosteroids) as a common factor in patients who developed serious infections. If you take or manage patients on adalimumab products, this update is relevant to safety monitoring, screening steps (TB testing), and age indications described in the label.
The entry is a regulatory drug-label record and does not present new clinical trial results beyond labeling decisions.
Keep In Mind
This record is a regulatory drug-label update (DailyMed / FDA). It summarizes approved indications and boxed warnings; it is not a research report or clinical-trial result. Follow your clinician for individualized medical advice about use, monitoring, and risks.
Source Details
Review the original publication for the complete reporting, methods, and context.
Regulatory update
Evidence type derived from source or registry metadata.
PublicationopenFDA
Study typeDrug Label Update
Indexed viaopenFDA
Source typeRegulatory record
PublishedJul 8, 2026, 12:00 AM
Content availableRegulatory record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
ABRILADA FDA label update (2026-06-18)
This FDA label update adds or confirms ABRILADA (an adalimumab product) as an approved TNF-blocker option for Crohn’s disease (including children ≥6) and ulcerative colitis (adults). It emphasizes infection and...
Adalimumab FDA label update (2026-07-08)
The label confirms adalimumab is approved for Crohn’s disease and ulcerative colitis and includes boxed safety warnings—information that directly affects patients considering or taking this TNF‑blocking biologic.
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
A new ustekinumab biosimilar (SELARSDI) is now available in the U.S. for Crohn’s disease and ulcerative colitis, which may expand treatment options and affect access or cost for patients on biologic therapy.